Subscribe for free <a href="biotechblueprint.substack.com" target="_blank" rel="noopener noreferer">HERE</a>. Gilead’s HIV breakthrough, Lilly’s $1.3B gene editing deal, and FDA reform efforts. Listen to the biggest news from biotech and pharma this week (June 13–19, 2025).

Subscribe for free HERE. Gilead’s HIV breakthrough, Lilly’s $1.3B gene editing deal, and FDA reform efforts. Listen to the biggest news from biotech and pharma this week (June 13–19, 2025).

Subscribe for free <a href="biotechblueprint.substack.com" rel="noopener noreferrer">HERE</a>. Gilead’s HIV breakthrough, Lilly’s $1.3B gene editing deal, and FDA reform efforts. Listen to the biggest news from biotech and pharma this week (June 13–19, 2025).

HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.

For more content, please subscribe to biotechblueprint.substack.com.

Technology

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

Share HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57

Sign up to save your podcasts

HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57

HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57